Skip to main content
Top
Published in: Journal of Gastroenterology 5/2020

01-05-2020 | Helicobacter Pylori | Editorial

How long should patients be surveyed for gastric cancer risk after Helicobacter pylori eradication therapy? 10 years is no longer enough

Authors: Mitsushige Sugimoto, Masaki Murata, Takashi Kawai

Published in: Journal of Gastroenterology | Issue 5/2020

Login to get access

Excerpt

Helicobacter pylori infection is a major risk factor for the development of gastric cancer, particularly in East Asian populations, including Japan. Gastric cancer is caused by a multifactorial and multistep process mainly related to long-term infection with H. pylori in the gastric mucosa. Nevertheless, eradication treatment for H. pylori infection has also been shown to reduce the risk of gastric cancer in patients with atrophic gastritis, and recent meta-analyses confirmed the same effect in patients after endoscopic and operative resection for gastric cancer [1-3]. The Maastricht V/Florence Consensus Report issued by the European Helicobacter Study Group in 2017 recommended the eradication of H. pylori as first-line treatment in patients with peptic ulcer disease, autoimmune thrombocytopenia, chronic urticaria, iron deficiency anemia, gastric mucosa associated-lymphoid tissue lymphoma, and functional dyspepsia as a means of preventing gastric cancer [4]. For the first time anywhere, the Japanese health insurance system initiated coverage of H. pylori eradication treatment in all patients with endoscopically confirmed H. pylori-associated gastritis in 2012. Against annual gastric cancer death rates of around 50,000 extending back more than 40 years, this expansion of coverage led to a significant decrease in deaths, from 48,427 in 2013 to 45,509 in 2016 [5]. National gastric cancer screening programs with upper endoscopy may have contributed to this decrease by decreasing the risk of diagnosis at an advanced stage, and by H. pylori eradication therapy after endoscopic diagnosis of H. pylori infection [6]. To date, however, most studies investigating the incidence of gastric cancer after eradication therapy have done so over the relatively short period of about 10 years, and it has remained unclear whether the chemopreventive effect of eradication therapy extends beyond 10 years, in consideration of pathological differentiation and the severity of gastric mucosal atrophy. …
Literature
1.
go back to reference Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22:435–45.CrossRef Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22:435–45.CrossRef
2.
go back to reference Yoon SB, Park JM, Lim CH, et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19:243–8.CrossRef Yoon SB, Park JM, Lim CH, et al. Effect of Helicobacter pylori eradication on metachronous gastric cancer after endoscopic resection of gastric tumors: a meta-analysis. Helicobacter. 2014;19:243–8.CrossRef
3.
go back to reference Xiao S, Li S, Zhou L, et al. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis. J Gastroenterol. 2019;54:226–37.CrossRef Xiao S, Li S, Zhou L, et al. Helicobacter pylori status and risks of metachronous recurrence after endoscopic resection of early gastric cancer: a systematic review and meta-analysis. J Gastroenterol. 2019;54:226–37.CrossRef
4.
go back to reference Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.CrossRef Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.CrossRef
6.
go back to reference Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology. 2017;152(1319–1328):e7. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology. 2017;152(1319–1328):e7.
8.
go back to reference Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.CrossRef Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1:87–97.CrossRef
9.
go back to reference Yamaoka Y, Orito E, Mizokami M, et al. Helicobacter pylori in North and South America before Columbus. FEBS Lett. 2002;517:180–4.CrossRef Yamaoka Y, Orito E, Mizokami M, et al. Helicobacter pylori in North and South America before Columbus. FEBS Lett. 2002;517:180–4.CrossRef
10.
go back to reference Yamaoka Y, El-Zimaity HM, Gutierrez O, et al. Relationship between the cagA 3 repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology. 1999;117:342–9.CrossRef Yamaoka Y, El-Zimaity HM, Gutierrez O, et al. Relationship between the cagA 3 repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH. Gastroenterology. 1999;117:342–9.CrossRef
11.
go back to reference Sugimoto M, Ohno T, Yamaoka Y. Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of Helicobacter pylori-infected Mongolian gerbils. J Gastroenterol. 2011;46:1177–86.CrossRef Sugimoto M, Ohno T, Yamaoka Y. Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of Helicobacter pylori-infected Mongolian gerbils. J Gastroenterol. 2011;46:1177–86.CrossRef
12.
go back to reference Sugimoto M, Ohno T, Graham DY, et al. Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci. 2009;100:2152–9.CrossRef Sugimoto M, Ohno T, Graham DY, et al. Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci. 2009;100:2152–9.CrossRef
Metadata
Title
How long should patients be surveyed for gastric cancer risk after Helicobacter pylori eradication therapy? 10 years is no longer enough
Authors
Mitsushige Sugimoto
Masaki Murata
Takashi Kawai
Publication date
01-05-2020
Publisher
Springer Singapore
Published in
Journal of Gastroenterology / Issue 5/2020
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-020-01674-y

Other articles of this Issue 5/2020

Journal of Gastroenterology 5/2020 Go to the issue